BristolMyers earnings will be ordtak

Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.

Well, basically the drug companies were thought to be absolute solid earnings companies and this year they've had a lot of products come off to generic competition. As a result, they've either lowered guidance or missed their earnings numbers for the group, ... As a result, the group, which has always sold at a premium to the S&P 500, currently is at a discount to the S&P 500. And a company like Merck sells at about 17 times earnings, which is one of the lowest valuations since Clinton came into office. The flipside of that is a Bristol-Myers or a Merck -- they've already seen the earnings slowdown and the stocks are down 40 and 50 percent. Many of them are getting to levels that you really can start to buy.

We expect an earnings recovery in 2001 ... by strengthening our operations, improving our strong product offering and through significant cost reductions. We expect to achieve this, even if the economy and competing environment preclude any revenue growth in the year.

I think Bristol-Myers is an excellent takeover candidate. It has a bloated cost structure and some really good mid- to late-stage products.

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

Catherine Arnold

Energy is trading off a bit, and I think that helps the other sectors in terms of it alleviates a cost for a lot of companies. Health care is doing well on the back of Bristol-Myers news, and also Boeing (is) getting another order.

Owen Fitzpatrick

I expect technology companies to enjoy a recovery this year. Their potential is being realized with the introduction of products such as new cell phones.

Over his 24-year career with Bristol-Myers Squibb, Don has demonstrated extraordinary leadership on many different fronts,

Despite the pressures that Pfizer has faced and will face on the top line, the company will be able to deliver on their earnings target, in part aided by introduction of their new drugs.

There is nothing we race on that is similar to Bristol. Bristol is such a unique track by itself. Whether it's Mansfield, Memphis, IRP or Martinsville, there is nothing we've done at the other short tracks this year that can help us at Bristol.

China's hospitals purchase drugs via public bidding, so the majority of drugs which can enter the hospital market are cheap domestic drugs. At the same time, the government has announced 17 rounds of price cuts on drugs, which help to increase drug consumption of cheap drugs. Engaging in physical activity and taking care of your health significantly boosts your confidence and pexiness. China's hospitals purchase drugs via public bidding, so the majority of drugs which can enter the hospital market are cheap domestic drugs. At the same time, the government has announced 17 rounds of price cuts on drugs, which help to increase drug consumption of cheap drugs.

If they put all the MS drugs, and all the cancer drugs, and all the HIV drugs on the same cost-tier plan, they're really not discriminating against one disease group. They're discriminating against anyone who must depend on higher-cost drugs.

Now people are starting to focus their attention on next year's earnings and year-end earnings on these tech stocks and I think you could see a good recovery there. Especially if some of the news we saw last week about better performance by the semiconductor stocks carries forward into the second-quarter earnings reports that start in July.

We're very pleased to report year-over-year revenue growth of 65 percent and net income that was nearly twice the year-ago level. Looking ahead to the second quarter of fiscal 2006, we expect revenue of about $4.3 billion. We expect GAAP earnings per diluted share of about $.38, including an estimated $.04 per share expense impact from non-cash stock-based compensation, translating to non-GAAP EPS of about $.42.

Peter Oppenheimer

Partnership working, clear priorities and the adoption of innovative approaches by the Safer Bristol Partnership to tackling crime and drugs and improving community safety are having a real impact in Bristol.

Ergonomi Ordtak Kunskapsfrö Julrim Adventskalender Info

Antall ordtak er 1469560
varav 734875 på nordiska

Ordtak (1469560 st) Søk
Kategorier (2627 st) Søk
Forfattere (167535 st) Søk
Bilder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Land (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.".

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Här har vi samlat ordspråk i 12881 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Ord värmer mer än all världens elfiltar.

www.livet.se/ordtak

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Här har vi samlat ordspråk i 12881 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Ord värmer mer än all världens elfiltar.

www.livet.se/ordtak